WP
BMY.RT

Woodline Partners’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Woodline Partners’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-902,102
Closed – – 501
2020
Q4 		$0 Buy
902,102
+755,183
+514% +$1.61M ﹤0.01% 293
2020
Q3 		$331K Buy
+146,919
New +$420K 0.01% 177

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Woodline Partners's BMY.RT Position: Q1 2021 in Review

Woodline Partners sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 902,102 shares.

Woodline Partners first reported a position in BMY.RT in Q3 2020 and held it in 2 quarters. The position peaked at $331K in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Woodline Partners reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Woodline Partners sold 902,102 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Woodline Partners first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q3 2020 and held it in 2 quarters.
  • Woodline Partners's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $331K in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Woodline Partners's 13F filing for Q1 2021, filed 17 May 2021.